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Evidence  suggests  that  anomalous  mismatch  negativity  (MMN)  in  schizophrenia  is related  to gluta-
matergic  abnormalities,  possibly  involving  N-methyl-d-aspartate  (NMDA)  receptors.  Decreased  cortical
expressions  of  NMDA  receptor  subunits  have  been  observed  in  schizophrenia,  though  not  consistently.  To
aid with  integration  and interpretation  of  previous  work,  we performed  a meta-analysis  of  effect  sizes of
mRNA  or  protein  levels  of the obligatory  NR1 subunit  in prefrontal  cortex  from  people  with  schizophre-






interval:  −1.08  to  −0.20)  for NR1  mRNA  reduction  and −0.44  (95%  conﬁdence  interval:  −0.80  to  −0.07)
for NR1  protein  reduction.  These  results  represent  the ﬁrst  step  to a deeper  understanding  of  the  region-
speciﬁc,  cell-speciﬁc,  and  stage-speciﬁc  NMDA  receptor  hypofunction  in  schizophrenia,  which  could  be
linked  to mismatch  negativity  deﬁcits  via  transgenic  and pharmacological  animal  models.
Crown Copyright  © 2015 Published  by Elsevier  B.V.  This  is  an  open  access  article  under  the CC
ismatch negativity
ntroduction
Mismatch negativity (MMN), an electrophysiological response,
s elicited when a regularly repeated invariant sequence of sounds
s occasionally interrupted by an infrequent sound deviating in
 simple physical dimension such as pitch (frequency) or length
duration) (Naatanen, Kujala, & Winkler, 2011b). MMN  signals that
he deviant sound was not what was expected and is based on the
rain detecting a difference between the deviant sound and the
ensory or echoic memory trace encoding the preceding regular
ounds—that is MMN  indexes an “error” in the implicitly learned or
ncoded “prediction model” (Naatanen, Jacobsen, & Winkler, 2005).
MN reﬂects automatic or pre-attentive sensory processing and is
∗ Corresponding author at: Schizophrenia Research Laboratory, Neuro-
cience Research Australia, PO Box 1165, Randwick, NSW 2031, Australia.
ax: +61 2 9399 1005.
E-mail address: v.catts@NeuRA.edu.AU (V.S. Catts).
ttp://dx.doi.org/10.1016/j.biopsycho.2015.10.013
301-0511/Crown Copyright © 2015 Published by Elsevier B.V. This is an open access ar
d/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
elicited regardless of whether the subject is paying attention to the
sounds. The generation (sources) of MMN  include activation within
primary auditory cortex (Heschl’s gyrus) and non-primary audi-
tory cortex (superior temporal gyrus [STG] or auditory association
areas): it is regarded as a sensitive index of central auditory system
plasticity (Naatanen, 2008). Hence, the discovery of MMN  deﬁcits
(particularly reduced amplitude) in schizophrenia reinforced the
notion that the pathophysiology of this disease speciﬁcally affects
multiple aspects of cortical plasticity (Baldeweg & Hirsch, 2015)
Deﬁcits in MMN  are evident at all stages of schizophre-
nia: prodromally (Bodatsch, Brockhaus-Dumke, Klosterkotter, &
Ruhrmann, 2015), at ﬁrst episode (Atkinson, Michie, & Schall,
2012; Nagai et al., 2013; Todd et al., 2008) and in late stage dis-
ease (Umbricht & Krljes, 2005) irrespective of whether patients
are taking antipsychotic medication or not (Catts et al., 1995;
Korostenskaja et al., 2005; Umbricht et al., 1999). In early-stage
schizophrenia, duration-deviant MMN  deﬁcits are more apparent
than frequency-deviant MMN  deﬁcits (Atkinson et al., 2012; Nagai
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t al., 2013; Todd et al., 2008) whereas patients with late-stage
chizophrenia consistently show deﬁcits in frequency-deviant
MN as well as duration-deviant MMN  (Atkinson et al., 2012;
alisbury, Shenton, Griggs, Bonner-Jackson, & McCarley, 2002;
odd et al., 2008; Umbricht & Krljes, 2005), though the relationship
etween stage-of-illness and deviant type needed to elicit MMN
eﬁcits has recently been challenged (Hay et al., 2015). Support for
MN  as “a breakthrough biomarker” for psychotic disorders (Light
 Naatanen, 2013) are ﬁndings of robust relationships between
MN  deﬁcits and the most consistent features of schizophrenia
ncluding psychosocial deterioration (Light & Braff, 2005; Rasser
t al., 2011; Rissling et al., 2014; Wynn, Sugar, Horan, Kern, & Green,
010), cognitive deﬁcits (Baldeweg, Klugman, Gruzelier, & Hirsch,
004; Kaur, Battisti, Ward, Ahmed, Hickie, & Hermens, 2011;
awakubo et al., 2006; Kiang et al., 2007; Miyanishi, Sumiyoshi,
iguchi, Seo, & Suzuki, 2013; Naatanen et al., 2011a), and reduced
ray matter volumes affecting mainly superior temporal and pre-
rontal cortex (PFC) (Rasser et al., 2011). Longitudinally progressive
ncreases in MMN  deﬁcits correlate with progressive reduction
f auditory cortical volumes (Salisbury, Kuroki, Kasai, Shenton, &
cCarley, 2007). Strengthening the evidence that MMN  deﬁcits
eﬂect schizophrenia-speciﬁc pathophysiology are studies showing
MN deﬁcits have predictive value in identifying individuals with
rodromal symptoms who in fact transition to psychosis (reviewed
y Naatanen, Shiga, Asano, & Yabe, 2015). Therefore, understanding
he neural basis of MMN  could shed light on disease processes.
The major cortical sources for MMN  are located bilater-
lly in primary and secondary auditory cortex (Alho, 1995),
hough extending to a broader frontal, temporal, and parietal
etwork (Fulham et al., 2014). Intra-cortical recordings in the
acaque suggest that deviant-related negativity in the MMN
esponse is generated in lamina II/III of the auditory cortex (Javitt,
teinschneider, Schroeder, Vaughan, & Arezzo, 1994). Dynamic
ausal modeling has provided evidence that MMN  deﬁcits in
chizophrenia relate primarily to impaired connectivity within
rimary auditory cortex, and secondarily to impaired connectiv-
ty between prefrontal and auditory areas (Dima, Frangou, Burge,
raeutigam, & James, 2012). MMN  deﬁcits appear to reﬂect prob-
ems in encoding rather than retention of the sensory trace (Javitt,
trous, Grochowski, Ritter, & Cowan, 1997; March et al., 1999).
eﬁcits in schizophrenia can best be explained by the MMN  ampli-
ude reaching asymptote at an earlier potential (or lower ceiling)
hereby reducing the dynamic range with which the brain can rep-
esent the environment (reviewed in Todd, Michie, Schall, Ward, &
atts, 2012).
Pharmacological studies using phencyclidine (PCP) and its ana-
ogues in both animals and humans show that the memory-based
omparison process underlying MMN  is critically dependent on the
ctivity of N-methyl-d-aspartate (NMDA) receptors (Ehrlichman,
axwell, Majumdar, & Siegel, 2008; Javitt, Steinschneider,
chroeder, & Arezzo, 1996; Kreitschmann-Andermahr et al., 2001;
ikhonravov et al., 2008; Umbricht et al., 2000). PCP and its
nalogues, ketamine and dizocilpine (MK-801), bind at the intra-
hannel site of the NMDA receptor to prevent calcium ion inﬂux into
he cell. Both pyramidal cells and interneurons express functional
MDA receptors (Monyer, Burnashev, Laurie, Sakmann, & Seeburg,
994). Animals administered non-competitive NMDA receptor
ntagonists show homologous behavior and cognitive deﬁcits to
he PCP-induced psychotomimetic effects observed in healthy
uman volunteers and individuals with schizophrenia (reviewed in
atts & Catts, 2010). Insights into the neuronal mechanisms under-
ying PCP-induced psychotomimetic effects have been obtained
rom in vivo electrophysiological studies, which demonstrate that
ingle dose administration of NMDA receptor antagonists induces
ustained large increases in prefrontal excitatory ﬁring and release
f glutamate by blocking the activity of inhibitory interneuronsology 116 (2016) 57–67
(Homayoun & Moghaddam, 2007; Moghaddam & Javitt, 2012). It
is thought that blockade of NMDA receptors preferentially acts
on fast spiking GABAergic interneurons because these neurons
have a more depolarized membrane potential and consequently
more open NMDA receptor channels (Moghaddam & Javitt, 2012).
Disinhibition of pyramidal cell ﬁring in turn leads to break-
down of synchronised connectivity between neuronal assemblies
intra-cortically and excessive cortical discharge to subcortical cen-
tres (Marin, 2012). These observations have been incorporated
into the NMDA receptor hypofunction model of schizophrenia,
which proposes a functional deﬁcit of NMDA receptor predomi-
nantly affecting interneurons and resulting in a loss of GABAergic
inhibitory control over glutamatergic pyramidal cells (Gordon,
2010). The PCP model and neuron-speciﬁc NMDA receptor sub-
unit expression knock-out animal models suggest that a deﬁcit
in either interneurons or pyramidal cells is sufﬁcient to cre-
ate a hyper-excited cortex (Billingslea et al., 2014; Carlen et al.,
2012; Korotkova, Fuchs, Ponomarenko, von Engelhardt, & Monyer,
2010; Tatard-Leitman et al., 2015). The literature also supports a
staged glutamatergic pathology in which initial hyper-excitability
has downstream compensatory consequences, which may lead to
hypo-excitability eventually.
The ﬁrst study to demonstrate the sensitivity of MMN  to
NMDA receptor function was  conducted in the rhesus macaque,
which showed a dose-dependent reduction in MMN  following local
intra-auditory cortical infusion of PCP (Javitt et al., 1996) and no
signiﬁcant effect of PCP on response to the repetitive sounds (stan-
dards). In humans, dose dependent reductions of MMN  amplitude
after a single injection of ketamine have been consistently reported
(reviewed in Todd, Harms, Schall, & Michie, 2013). Dynamic causal
modeling applied to data from one acute ketamine challenge study
in healthy humans (Schmidt et al., 2013) indicated that ketamine
selectively reduced the normal increase in synaptic plasticity in
the forward connection between left primary auditory cortex and
left STG in response to the deviant tones. This appears to be some-
what in contrast with late-stage schizophrenia which is principally
thought to be associated with reduced intrinsic connections within
primary auditory cortex and signiﬁcant alteration in prefrontal STG
connections (Dima et al., 2012). Analogous MMN  deﬁcits have been
found in rodent models of NMDA receptor hypofunction, either
genetically- (e.g., Featherstone et al., 2015b) or pharmacologically-
induced (e.g., Sivarao, 2015). These studies are reviewed elsewhere
(Harms, 2016). Though there are concerns about the translational
validity of MMN  in the rodent (Harms, Michie, & Naatanen, 2016),
the homology of MMN  ﬁndings across non-human primates and
humans is particularly impressive (Gil-Da-Costa, Stoner, Fung, &
Albright, 2013; Javitt et al., 1996). In summary, there is now general
acceptance that NMDA receptor-related neurotransmission is criti-
cal for the generation of MMN  and that pre-clinical models of NMDA
receptor hypofunction are associated with MMN  deﬁcits similar to
those observed in schizophrenia. The question this research raises
is: “how strong is the evidence that NMDA receptor hypofunction
is central to the pathophysiology of schizophrenia?”.
Converging evidence from several distinct lines of research sug-
gests that NMDA receptor hypofunction may contribute to the
expression of schizophrenia. Firstly, there are clinical studies of
the deleterious behavioral effects of non-competitive NMDA recep-
tor antagonists, with evidence of chronic use of PCP inducing
psychotic disorder beyond the acute symptoms of intoxication
(reviewed in Catts & Catts, 2010). Epidemics of PCP abuse in
the U.S.A. during the 1960s and 1970s were regionally and tem-
porally discrete, demonstrating a consistent association between
heavy PCP use and epidemics of ﬁrst admission schizophrenia,
with most admissions occurring in young people with neither
family history of schizophrenia nor displaying other premorbid
risk factors (Fauman & Fauman, 1978; Luisada, 1978; Pearlson,


































































Fig. 1. Identiﬁcation of literature for qualitative review and meta-analysis. Data
collections that quantiﬁed the total expression of the obligatory NMDA receptor
subunit NR1 in the prefrontal cortex of people with schizophrenia were used to
determine effect sizes, which were entered into meta-analyses, with two exceptions.
One  data collection on NR1 mRNA and two on NR1 protein were excluded from
meta-analyses because insufﬁcient data were available for calculation of effect sizes
(Dracheva et al., 2001; Emamian et al., 2004). A data collection (Kristiansen et al.,
2006) on protein expression in the anterior cingulate cortex (ACC) was excludedV.S. Catts et al. / Biologica
981; Peterson and Stillman, 1978). Secondly, further evidence for
he involvement of NMDA receptor hypofunction in schizophre-
ia comes from the recently described NMDA receptor encephalitis
Dalmau et al., 2007), in which individuals with high CSF titers of
utoantibodies against NMDA receptor subunits develop psychosis
Dalmau, Lancaster, Martinez-Hernandez, Rosenfeld, & Balice-
ordon, 2011). In vitro studies suggest that antibodies against
he NMDA receptor cause receptor endocytosis indiscriminately of
euronal type (Moscato et al., 2014). Thirdly, enhancing NMDAR
unction via increasing availability of co-agonists has efﬁcacy in at
east a subgroup of patients in clinical trials in schizophrenia (Kinon,
illen, Zhang, & McKinzie, 2015; Tuominen, Tiihonen, & Wahlbeck,
005) though not all studies show this effect (Carpenter et al.,
005). Fourthly, the serine racemase knock-out mouse (a model of
MDA hypofunction) has a schizophrenia-related phenotype with
mpaired long-term potentiation, reduced hippocampal volume,
nd impaired memory (Balu et al., 2013). Finally, NMDA recep-
or involvement in schizophrenia is suggested by genetic studies,
hich implicate not only NMDA receptor subunits directly, but
lso multiple other molecules involved in glutamatergic signaling
Fromer et al., 2014; Purcell et al., 2014). The largest genome wide
ssociation study in schizophrenia to date identiﬁed genetic linkage
o an intronic single nucleotide polymorphism within the GRIN2A
ene (Ripke et al., 2014) encoding the NR2A NMDA receptor sub-
nit. Analyses of de novo copy number variations also implicate
MDA receptors, with enrichment of nonsynonymous polymor-
hisms and loss of function mutations in the GRIN2A gene in
ndividuals with schizophrenia (Fromer et al., 2014; Kirov et al.,
012). That is, there is clinical, experimental, and genetic evidence
hat NMDA receptor hypofunction is sufﬁcient to induce a pheno-
ype resembling schizophrenia. However, this evidence does not
ndicate whether NMDA receptor hypofunction is a necessary com-
onent of the pathophysiology nor does it clarify the speciﬁc brain
echanism causing NMDA hypofunction at a cellular, network, or
ystems level. In particular, this evidence does not clarify whether
MDA receptor hypofunction is due to an endogenous abnormality
f the receptor itself.
The NMDA receptor consists of four subunits, two  of which must
e the obligatory NR1 subunit for the receptor to be functional,
hereas the other two subunits can be any of four NR2 or two NR3
ubunits. The NR1 subunit binds glycine and d-serine (Mothet, Le
ail, & Billard, 2015). Expression of the obligatory NR1 subunit is
ainly restricted to neurons, due to a consensus neuron restrictive
ilencer element (NSRE) in exon 1 of the GRIN1 gene (Bai, Norton,
renger, & Kusiak, 1998; Okamoto, Sherman, & Lipton, 1999). In
uman cortex, NR1 expression increases from low prenatal levels
o a peak at 11–15 years of age and remains relatively stable into
dulthood (Catts et al., 2013; Henson et al., 2008). The NR2 sub-
nits (NR2A, NR2B, NR2C and NR2D) bind glutamate. NR2A and
R2B subunits predominate in the adult cortex and are expressed
n both interneurons and pyramidal cells (Monyer et al., 1994). In
uman brain, NR2B expression peaks around birth and decreases
n parallel with an increase in NR2A expression (Catts et al., 2013;
aw et al., 2003). The resulting decrease in NR2B/NR2A ratio across
he lifespan is thought to be responsible for decreased plasticity
ssociated with maturation and aging (Crair & Malenka, 1995). Cor-
ical NR2C and NR2D expressions appear to be mainly restricted to
ifferent subsets of interneurons (Monyer et al., 1994; Standaert,
andwehrmeyer, Kerner, Penney, & Young, 1996) and these sub-
nits confer low sensitivity to magnesium blockade of the receptor,
esulting in a rapid response to depolarisations (Clarke & Johnson,
006) and heightened susceptibility to channel blockers, such as
CP analogues (Kotermanski & Johnson, 2009). Human cortical
R2D expression is highest at birth (Catts et al., 2013; Choi, Zepp,
iggs, Weickert, & Webster, 2009), whereas human cortical NR2C
xpression over the lifespan remains to be fully characterised, per-because the subjects overlapped with another dataset on the dorsolateral prefrontal
cortex (DLPFC) presented in the same publication.
haps owing to its relatively low expression in cortex relative to the
cerebellum (Karavanova, Vasudevan, Cheng, & Buonanno, 2007).
The NR3 (NR3A and NR3B) subunits bind glycine, and therefore are
unique in forming excitatory glycine receptors when co-expressed
with NR1 (Chatterton et al., 2002). In the human PFC, NR3A expres-
sion is highest at birth and decreases steadily into adulthood (Catts
et al., 2013). NR3B is less well characterised in humans, but studies
of rodent brain indicate that there is ubiquitous expression of this
subunit in multiple neuron subtypes in the forebrain, and that the
expression gradually increases with age (Low & Wee, 2010). Thus,
not only do the various NMDA receptor subunits confer unique
properties to the NMDA receptor complex, they are differentially
expressed according to the age of the organism, brain region, and
neuronal type. It is important to consider the many possible per-
mutations and location of expression of the NMDA receptor, as each
may  uniquely contribute to the development of schizophrenia and
to generation of MMN  amplitude.
Without knowing which cell types are implicated in generating
MMN  amplitude and a detailed description of region-speciﬁc, cell-
speciﬁc, and stage-speciﬁc changes in NMDA receptor function in
schizophrenia, it is difﬁcult to link MMN  abnormalities to the glu-
tamatergic pathology in schizophrenia. Even basic information on
whether there are expression deﬁcits of the NMDA receptor sub-
units themselves in brains of individuals with schizophrenia, and if
so, which receptor subtypes are the most affected, remains contro-
versial despite recent major narrative reviews of the morphological
and molecular evidence in support of a cortical glutamatergic
dysfunction in schizophrenia (Featherstone et al., 2015a; Gonzalez-
Burgos & Lewis, 2008; Hu, MacDonald, Elswick, & Sweet, 2015;
Javitt & Sweet, 2015; Moghaddam & Javitt, 2012). As an impor-
tant step in addressing this knowledge gap, here we present the
ﬁrst published quantitative review by meta-analysis of NMDA
receptor subunit expression in postmortem brain from individuals
with schizophrenia, with the hypothesis of reduced cortical NMDA
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. Materials and methods
.1. Study selection
Primary studies on the expression of NMDA receptor subunits in patients with
chizophrenia were identiﬁed from electronic bibliographic searches of Web  of
cience throughout the period of 1 January 1990–29 April 2015 using the search
tring ‘(schizophrenia OR schizophrenic) AND (NMDA* OR ionotropic OR GRIN*)
ND (human OR patient OR postmortem OR post-mortem) AND expression’. Stud-
es  were also sourced from reference lists of published articles and from the authors’
ersonal libraries. Authors were contacted for further details when published data
id  not allow study inclusion in the meta-analysis. All identiﬁed studies describ-
ng cortical NMDA receptor subunit mRNA or protein expression in people with
chizophrenia are tabulated in Table 1.
.2. Meta-analysis
To achieve sufﬁcient study homogeneity and number, we restricted meta-
nalysis to studies quantifying total NR1 mRNA or protein expression in the PFC of
eople with schizophrenia (Fig. 1). There were too few studies assessing tissue from
he auditory cortex to subject them to meta-analysis. Data were tabulated accord-
ng to whether the measurement target was mRNA or protein expression. Where
RNA or protein expression was measured in more than one region in the PFC in
he same study sample (Kristiansen, Beneyto, Haroutunian, & Meador-Woodruff,
006), data from the dorsolateral prefrontal cortex (DLPFC) was  used in the meta-
nalysis because this was  the region most frequently assessed in other studies that
ere included. Effect size and conﬁdence intervals were calculated based on the
vailable data, i.e. sample sizes, means and standard deviations. Meta-analysis were
arried out using RevMan 5.3.5 (The Cochrane Collaboration, 2014) using random
ffects model to protect against heterogeneity of sampling. Pooled effect sizes and
5  percent conﬁdence intervals are reported.
. Results
Our Web  of Science search identiﬁed 473 unique publications,
f which 33 reported on the expression of NMDA receptor subunits
n individuals with schizophrenia. An additional four publications
ere identiﬁed from reference lists of the identiﬁed papers and
rom the authors’ libraries. Twelve of these 37 publications focused
n total NMDA receptor NR1 subunit expression in PFC from people
ith schizophrenia (Table 1; Fig. 1).
The ﬁnal meta-analyses of NR1 mRNA and of NR1 protein
xpressions are displayed in Fig. 2. The ﬁve studies of NR1
RNA included in the meta-analysis consisted of 94 subjects with
chizophrenia and 82 control subjects (Table 2). The pooled effect
ize for these studies was −0.64 (CI −1.08 to −0.20, p = 0.004), indi-
ating that the signiﬁcant decrease in expression of NR1 mRNA
n schizophrenia subjects relative to controls is of medium to
arge effect. The meta-analysis of the ﬁve studies of NR1 protein
Table 2), consisting of 95 subjects with schizophrenia and 95 con-
rols, yielded an effect size of −0.44 (CI −0.80 to −0.07, p = 0.02),),
ndicating that the signiﬁcant decrease in expression of NR1 pro-
ein in schizophrenia subjects relative to controls is of medium
ffect. Inputting these effect sizes into power analyses indicate that
ore than 30 subjects per group are required to reliably detect
tatistically signiﬁcant differences in NR1 expression when using
omogenised postmortem brain tissue from medicated chronically
ll patients with schizophrenia compared to controls.
Our qualitative review of the NR2 (A, B and D) and NR3A subunits
Table 1) studies suggested there are no consistent statistically
igniﬁcant changes in cortical mRNA expression or protein lev-
ls of these subunits. This is not surprising given the small effect
izes detected in our own  study (Weickert et al., 2013) for changes
n NR2A, 2B and 3A mRNA (0.15–0.24) in schizophrenia subjects
ompared to controls, which indicates that a much larger sam-
le size (n ≥ 200/group) is required to reliably detect diagnostic
ifferences in these mRNA expressions if they existed. A notable
xception is the diagnostic changes in NR2C, which reached the
elatively large effect size of d = 0.52 (Weickert et al., 2013). The
R2C subunit mRNA expression decrease in the PFC was  statisti-
ally signiﬁcant in all three published studies that examined thisology 116 (2016) 57–67
subunit (Akbarian et al., 1996; Beneyto & Meador-Woodruff, 2008;
Weickert et al., 2013). However, reductions in NR2C mRNA were not
evident in studies of temporal lobe regions (see Table 1) (Akbarian
et al., 1996; Beneyto, Kristiansen, Oni-Orisan, McCullumsmith, &
Meador-Woodruff, 2007). Reductions in NR2C protein were also
not observed in DLPFC or anterior cingulate cortex in a study using
an elderly cohort (see Table 1) (Kristiansen et al., 2006). In sum-
mary, studies of PFC show a fairly robust group-wise decrease in
NR1 and NR2C expression in schizophrenia compared to controls
with no clear evidence for changes in the other NR2 subunits. How-
ever, there is limited investigation of NR3 subunit expression in
schizophrenia.
3. Discussion
We  show by meta-analysis that expression of NR1 mRNA in the
PFC is signiﬁcantly decreased in subjects with schizophrenia com-
pared to controls, with the decrease being of medium to large effect
size. One study that assayed NR1 mRNA expression in the DLPFC
(BA46; Dracheva et al., 2001) had to be excluded from the meta-
analysis because an effect size could not be calculated. This study
of 26 elderly subjects with schizophrenia and 13 elderly controls
found an increase in NR1 mRNA in schizophrenia, contrary to the
results of our meta-analysis. A comparable study (Sokolov, 1998)
that measured NR1 mRNA expression in DLPFC tissue in a simi-
lar sized cohort of elderly subjects, from the same Schizophrenia
Brain Bank at Mount Sinai School of Medicine, found decreased NR1
mRNA expression. As both studies used quantitative PCR to mea-
sure NR1 and may  have assayed tissue from overlapping cohort of
brains, it is unclear why  their results vary from each other.
Our meta-analysis also found that expression of NR1 protein in
the PFC is signiﬁcantly decreased in subjects with schizophrenia
compared to controls. Though a similar number of studies were
entered into the protein meta-analysis as the NR1 mRNA meta-
analysis, the decrease in NR1 protein was  of medium effect size,
rather than of medium to large effect size as we found for NR1
mRNA. It was necessary to exclude three datasets from our PFC
NR1 protein meta-analysis. Two of these datasets were in one
publication (Emamian, Karayiorgou, & Gogos, 2004) but had to be
excluded because an effect size could not be calculated based on
the published data (one dataset yielded no difference in total NR1
protein, and the other a non-signiﬁcant increase, in subjects with
schizophrenia). The third protein study was excluded because of
overlap in the brain cohort with a study of DLPFC reported in the
same publication (Kristiansen et al., 2006), the latter is included in
our current meta-analysis. The excluded study of anterior cingu-
late cortex found no change in the levels of NR1 2C isoform levels
and a signiﬁcant increase in NR1 2C′ isoform levels in subjects with
schizophrenia (Kristiansen et al., 2006).
NR2C mRNA was  consistently found to be decreased in the
three studies that examined its expression in PFC in subjects
with schizophrenia. However NR2C protein was not decreased
in the anterior cingulate cortex or DLPFC in an elderly cohort
(Kristiansen et al., 2006). Reasons for the inability to replicate the
decreased mRNA transcript levels at a protein level include the pos-
sibility that NR2C protein, like NR2A and NR2B protein (Henson
et al., 2008) is unstable postmortem and therefore diagnostic
differences may  be more difﬁcult to detect. Also, the molecu-
lar techniques used to assay these levels quantitatively are quite
distinct and have different levels of sensitivity and amount of vari-
ability. That is, quantifying protein by Western blotting is a less
precise methodology than quantifying mRNA by real-time PCR and
in situ hybridization, and Western blotting may  be less sensitive in
demonstrating diagnostic differences. Additionally, we  found that
the NR2C mRNA deﬁcit is more apparent in individuals with a rel-
V.S. Catts et al. / Biological Psychology 116 (2016) 57–67 61
Table  1
Studies of cortical NMDA receptor subunit expression in schizophrenia, ranked by brain lobes, then publication year.
First author Year NR1 NR2A NR2B NR2C NR2D NR3A NR3B Brain region Methodology Sz N Con N
mRNA studies—frontal lobe
Akbarian 1996 • • • ↓ • Frontal pole In situ hybridisation 15 15
Sokolov 1998 ↓a Superior frontal gyrus qRT-PCR 21 9
Le  Corre 2000 • Middle frontal cortex In situ hybridisation 6 6
Dracheva 2001 ↑ • • Dorsolateral prefrontal cortex qRT-PCR 26 13
Mueller 2004 ↑ Dorsolateral prefrontal cortex In situ hybridisation 15 15
Woo  2004 ↓b Anterior cingulate cortex In situ hybridisation 17 17
Martucci 2006 • Dorsolateral prefrontal cortex qRT-PCR 35 35
Beneyto 2008 ↓ ↓ • ↓ • Prefrontal cortex In situ hybridisation 15 15
Woo  2008 ↑c Anterior cingulate cortex In situ hybridisation 20 20
Weickert 2013 ↓ • • ↓ • Dorsolateral prefrontal cortex qRT-PCR 37 37
mRNA studies—temporal lobe
Akbarian 1996 • • • • • Temporal cortex In situ hybridisation 15 15
Humphries 1996 ↓ Superior temporal cortex Slot blot 12 7
Le  Corre 2000 ↑ Superior temporal cortex In situ hybridisation 6 6
Mueller 2004 • Inferior temporal cortex In situ hybridisation 15 15
Beneyto 2007 • • • • • Perirhinal In situ hybridisation 15 15
Beneyto 2007 • • • • • Entorhinal In situ hybridisation 15 15
mRNA studies—occipital lobe
Le Corre 2000 • Occipital cortex In situ hybridisation 6 6
Dracheva 2001 ↑ ↑ • Occipital cortex qRT-PCR 26 13
Protein studies—frontal lobe
Emamian 2004 • Frontal cortex Western blotting 10 10
Emamian 2004 • Frontal cortex Western blotting 15 14
Toro 2005 • Orbitofrontal gyrus Immuno-autoradiography 15 15
Kristiansen 2006 •d • • • • Dorsolateral prefrontal cortex Western blotting 13 8
Kristiansen 2006 •e Dorsolateral prefrontal cortex Western blotting 13 8
Kristiansen 2006 •d • • • • Anterior cingulate cortex Western blotting 24 16
Kristiansen 2006 ↑e Anterior cingulate cortex Western blotting 24 16
Hahn 2006 ↑f Dorsolateral prefrontal cortex Western blotting 10 10
Henson 2008 • • Dorsolateral prefrontal cortex Western blotting 15 20
Kristiansen 2010 •g ↓g •h Dorsolateral prefrontal cortex Western blotting 13 8
Kristiansen 2010 •g •g Anterior cingulate cortex Western blotting 13 8
Errico 2013 ↓ ↓ ↓ Prefrontal cortex Western blotting 15 15
Weickert 2013 ↓ Dorsolateral prefrontal cortex Western blotting 37 37
Protein studies—temporal lobe
Nudmamud-Thanoi 2004 • Superior temporal cortex Western blotting 15 15
• = no statistically signiﬁcant change↓ = decreased expression↑ = increased expression.
a Including several medication free individuals with schizophrenia.
b Decrease in GAD67 positive neurons only.
c Increase in calbindin positive neurons only.
d Measure of the C2 NR1 splice variant.
e Measure of the C2′ NR1 splice variant.
f Associated with PSD-95 following isolation of post-synaptic density enriched fractions of tissue homogenates.
g In endoplasmic reticulum-enriched fraction.
h In total homogenate.
Table 2
Detailed demographic data from studies of NMDA receptor subunit expression in prefrontal cortex from individuals with schizophrenia included in the meta-analyses.
First author Year Brain region Methodology NR1 Sz Sex (F/M) Con Sex (F/M) Sz age (years) Con age (years) Sz PMI  (hours) Con PMI  (hours)
mRNA studies
Akbarian 1996 Frontal pole In situ hybridisation • 3/12 3/12 55.2 ± 5.4 57.4 ± 5.3 16.1 ± 2.2 15.1 ± 2.0
Sokolov 1998 Superior frontal gyrus qRT-PCR ↓a 8/13 4/5 73.4 ± 4.2 77. 4 ± 2.7 37.4 ± 7.6 5.4 ± 0.8
Le  Corre 2000 Middle frontal cortex In situ hybridisation • 1/5 1/5 46.6 ± 6.6 48.3 ± 5.6 22.6 ± 4.9 20.3 ± 3.6
Beneyto 2008 Prefrontal cortex In situ hybridisation ↓ 6/9 6/9 44.2 ± 13.1 48.1 ± 10.7 33.7 ± 14.6 23.7 ± 10.0
Weickert 2013 DLPFC qRT-PCR ↓ 13/24 7/30 51.3 ± 2.3 51.1 ± 2.4 28.8 ± 2.3 24.8 ± 1.8
Protein studies
Toro 2005 Orbitofrontal cortex Immuno-autoradiography • 6/9 6/9 44.2 ± 13.1 48.1 ± 10.7 33.7 ± 14.6 23.7 ± 10
Kristiansen 2006 DLPFC Western blotting •b 5/8 5/3 71.8 ± 2.8 79.8 ± 4.7 9.2 ± 1.6 5.1 ± 0.9
Henson  2008 DLPFC Western blotting • 5/10 5/15 54.3 ± 4.4 56.7 ± 4.1 21.7 ± 1.3 21.2 ± 1.3
Errico  2013 Prefrontal cortex Western blotting ↓ 7/8 7/8 61.7 ± 4.8 63.3 ± 4.6 57.2 ± 6.5 36.2 ± 5.8




d = no statistically signiﬁcant change↓ = decreased expression↑ = increased expressio
a Including several medication free individuals with schizophrenia.
b Measure of the C2 and C2′ NR1 splice variants separately.tively short duration of illness and is less apparent with increased
isease duration (Weickert et al., 2013), so it is possible that a
ecrease in NR2C protein may  not be evident in cohorts of elderlyFC = dorsolateral prefrontal cortex ± standard error of the mean.individuals with schizophrenia. Taken together, the studies above
suggest a NR2C expression deﬁcit could account for NMDA  recep-
tor dysfunction in interneurons in schizophrenia, though again it is






































tFig. 2. Meta-analysis of NR1 mRNA and NR1 protein expres
nknown what interneuron subtype is most impacted by the NR2C
eﬁcit.
While the studies reviewed using total homogenate or ﬁlm-
ased in situ hybridization techniques suggest that the NR2A
ubunit of the NMDA receptor is not greatly altered in people with
chizophrenia, two studies of NR2A subunit mRNA in interneu-
ons suggest otherwise. Using double-label in situ hybridization to
eﬁne interneuron populations, Woo  et al. (2004); Woo, Shrestha,
amb, Minns, and Benes (2008) found a decreased density of NR2A
RNA expressing GAD67 positive interneurons, but an increased
ensity in the subset of NR2A and calbindin mRNA-containing
eurons in layer II of anterior cingulate cortex. This is notewor-
hy, as the gene for NR2A has been implicated in the etiology
f schizophrenia in large genetics studies (Fromer et al., 2014;
ipke et al., 2014). It also relates to the more general question of
hich interneuron subtype is speciﬁcally affected by NMDA recep-
or hypofunction in schizophrenia. Several interneuron subtypes
ave been shown to be impacted in schizophrenia, with somato-
tatin and parvalbumin having the greatest expression deﬁcits
Beasley & Reynolds, 1997; Cotter et al., 2002; Fung, Fillman,
ebster, & Weickert, 2014; Fung et al., 2010; Hashimoto et al.,
008a; Hashimoto et al., 2008b; Lewis, 2000; Morris, Hashimoto, &
ewis, 2008) and calbindin shown to be increased in several stud-
es (Daviss and Lewis, 1995; Fung et al., 2014; Fung et al., 2010;
oo  et al., 2008). Our group has recently shown that somatostatin
nterneuron density is decreased in layer II of the orbitofrontal cor-
ex, and that this is associated with cell death receptor expression
Joshi, Catts, Olaya, & Shannon Weickert, 2015), making somato-
tatin interneurons a plausible candidate for the NR2A deﬁcit.
owever, maturation of parvalbumin-positive interneurons, and
ot somatostatin-positive interneurons, has been shown to be
electively affected by chronic blockade of NR2A (Zhang & Sun,
011), making parvalbumin-positive interneurons an interesting
andidate to link to NMDA receptor dysfunction. Examination of the
ensity of double-labelled NR2A mRNA and somatostatin-positive
r parvalbumin-positive interneurons is warranted, in order to
ocalize the putative NR2A deﬁcit to one or more interneuron sub-
ypes.vels in prefrontal cortex of individuals with schizophrenia.
With expression deﬁcits identiﬁed in possibly up to three dif-
ferent NMDA receptor subunits (NR1, NR2A and NR2C), the next
question arising is whether different individuals have different
NMDA receptor pathologies or whether expression deﬁcits in two
or more subunits co-occur in the same individual with schizophre-
nia. If there is co-occurrence of deﬁcits in two  or more subunits,
the next questions are whether both deﬁcits arise at once, or could
one be a consequence of the other, and do deﬁcits in two  or more
subunits co-occur in the same cells, or in different cell types? While
these questions may  be most readily addressed at the mRNA level
using dual-label in situ hybridization, there is also a role for pro-
tein studies, as these show altered trafﬁcking to (Kristiansen, Patel,
Haroutunian, & Meador-Woodruff, 2010), and signaling at (Catts,
Derminio, Hahn, & Shannon Weickert, 2015; Hahn et al., 2006), the
synapse in cortex from people with schizophrenia, thus demon-
strating a deﬁcit in receptor function.
Clinical and preclinical evidence supports stage-speciﬁc gluta-
matergic abnormalities in schizophrenia. Marsman et al. (2013)
reported a major meta-analysis of proton magnetic resonance spec-
troscopy (1H-MRS) studies of brain glutamine concentrations in
patients with schizophrenia. Because the majority of physiolog-
ical active glutamate is derived from glutamine, high levels of
glutamine is usually indicative of high glutamate levels and high
glutamatergic activity, though theoretically they could be due to
decreased catabolism of glutamine to glutamate. The 1H MRS  meta-
analysis found that overall prefrontal glutamate was decreased
and glutamine levels were increased in schizophrenia (Marsman
et al., 2013). When studies were divided into those assessing
early-stage versus late-stage schizophrenia, the abnormalities in
prefrontal glutamine levels were in opposite directions in the
two groups. The four studies that assessed early-stage patients
revealed a large increase in prefrontal glutamine levels (effect
size in the order of 1.0), while the four studies assessing late-
stage schizophrenia showed decreases (effect size in the order of
0.5). Thus, early-stage schizophrenia appears to be associated with
excessive glutamatergic activity whilst late-stage schizophrenia
shows deﬁcient glutamatergic activity.
The results of ketamine challenge studies in humans could be
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tudies (that is, brief NMDA receptor antagonist exposure) are
ompared with ﬁndings in chronic PCP abusers (repeated and long-
erm NMDA receptor antagonist exposure), single-dose ketamine
nduces prefrontal hyper-activation (Rowland et al., 2005; Stone
t al., 2012) whereas chronic PCP abuse is associated with pre-
rontal hypo-activation (Hertzman, Reba, & Kotlyarov, 1990; Wu,
uchsbaum, Potkin, Wolf, & Bunney, 1991). A study of PFC connec-
ivity in healthy human volunteers after a single dose of ketamine
ound hyper-connectivity similar to that observed in individuals
t high risk of psychosis and early psychosis patients, but not in
hose with chronic schizophrenia (Anticevic et al., 2015). In rodent
tudies, single dosing with NMDA receptor antagonists causes
ncreased activation in frontal regions (Duncan, Leipzig, Mailman,
 Lieberman, 1998), whereas repeat dosing causes reduced pre-
rontal activation (Cochran et al., 2003). Thus, the clinical and
re-clinical research indicates that only brief exposure to NMDA
eceptor antagonists produces a picture consistent with the NMDA
eceptor hypofunction model of schizophrenia (with pyramidal
ell disinhibition and cortical hyper-activity) whilst prolonged
xposure produces a picture inconsistent with the original model
implicating hypo-activation in pyramidal cells). This interpreta-
ion is consistent with the 1H MRS  data in schizophrenia providing
onvergent support for disease stage-dependent differences in glu-
amatergic abnormalities. We  propose a revised NMDA receptor
ypofunction model of schizophrenia where the early stages of
chizophrenia are characterized by an NMDA receptor deﬁcit pre-
ominantly in interneurons (NR2A and/or NR2C), which leads to
nder-activity of the NMDA receptor on interneurons and thus
ess inhibition and more excitation of pyramidal neurons. This in
urn eventually may  lead to a compensatory decrease in NMDA
eceptor expression in pyramidal neurons (NR1) as the disease pro-
resses and may  be in response to increased glutamate over time
nd enduring low level but cumulative excitotoxicity. This proposal
equires speciﬁcation of the cell types affected early and late in
he course of schizophrenia to determine primacy and directional-
ty. Further support for the revision of the original NMDA receptor
ypofunction model of schizophrenia, especially in terms of the
eed to also incorporate a deﬁciency of NMDA receptors in pyra-
idal cells, is provided by the research using postmortem tissue
omogenate (Sokolov, 1998; Weickert et al., 2013) and ﬁlm-based
n situ hybridization (Akbarian et al., 1996; Beneyto & Meador-
oodruff, 2008; Le Corre, Harper, Lopez, Ward, & Catts, 2000). As
nterneurons account for only about 20% of all neurons in the PFC
Marin, 2012) and have lower abundance of NR1 protein than pyra-
idal cells (at least at the synapse; Nyiri, Stephenson, Freund, &
omogyi, 2003), then a decrease in cortical NR1 protein expression
f up to 36% in schizophrenia (Weickert et al., 2013) is unlikely to
e restricted solely to interneurons.
We  have demonstrated by meta-analysis direct postmortem
vidence of NMDA receptor hypofunction in schizophrenia, at least
n the PFC. We  have also argued that NMDA receptor-related neu-
otransmission is critical for the generation of MMN  and that
re-clinical models of NMDA receptor hypofunction are associated
ith MMN  deﬁcits similar to those observed in schizophrenia. We
ow address the unanswered question: can we  link the two lines of
esearch to create a framework for elucidating the neuropathology
f schizophrenia through an understanding of the neurobiology of
MN? Within each level of description, schizophrenia and MMN
ave corresponding characteristics to suggest that an understand-
ng of one will inform the nature of the other. Structurally, the most
ominant pattern of reduced grey matter volume associated with
chizophrenia affects the STG and prefrontal regions (Gupta et al.,
015), the same neuroanatomical areas that house primary MMN
enerators, and not surprisingly in schizophrenia MMN  deﬁcits
orrelate with grey matter reductions in the STG (Rasser et al.,
011; Salisbury et al., 2007). Functionally, MMN  activates the sameology 116 (2016) 57–67 63
networks (Alho, 1995; Fulham et al., 2014) that show altered con-
nectivity in schizophrenia (Friston & Frith, 1995; Liu et al., 2008):
these networks are also altered in relation to the MMN  deﬁcits in
schizophrenia (Gaebler et al., 2015). At the level of circuitry, the
same intra-cortical and inter-cortical circuits involved in MMN  gen-
eration (Javitt, 2015; Javitt & Sweet, 2015; Todd et al., 2013) appear
to be altered in schizophrenia (Lewis, 2012; Moghaddam & Javitt,
2012). At the cellular level, models for MMN  generation are impres-
sively similar to models for schizophrenia, namely as an alteration
in the balance between glutamatergic (pyramidal cell) excitation
and GABAergic (interneuronal cell) inhibition (reviewed in Todd
et al., 2013). While this formulation is far too imprecise to guide
a research program aimed at linking the two  lines of research, it
does clearly indicate that the focus of such a program should be on
comparing and contrasting NMDA receptor dysfunction in speciﬁc
interneurons and in pyramidal cells in the cortex.
Reinforcing this notion is the literature on EEG oscillatory activ-
ity (resting state and steady state oscillations), particularly the
gamma  band frequency band (25–100 Hz but typically 40 Hz). Fast-
ﬁring parvalbumin positive (inhibitory GABAergic) interneurons
are essential for the production of synchronised neuronal ﬁring
and network oscillations (Gonzalez-Burgos & Lewis, 2008), but
recent evidence emphasises interactions between interneurons
and pyramidal cells and the centrality of the role of the NMDA
receptor in production of cortical oscillations (Cardin et al., 2009;
Carlen et al., 2012; Carracedo et al., 2013; Kirli, Ermentrout, & Cho,
2014; Sivarao, 2015). In schizophrenia: task-induced gamma-band
oscillations have reduced power and synchronisation (reviewed in
Andreou et al., 2015); steady state auditory evoked potentials have
reduced power, particularly in the gamma frequency (O’Donnell
et al., 2013); and resting state gamma  band connectivity increased
(Andreou et al., 2015). Importantly, MMN  and its schizophrenia-
related deﬁcits are tightly linked with oscillatory activity both
at the gamma  (Ballesteros et al., 2013; Nicol et al., 2012) and
theta (Kaser et al., 2013) frequencies, these frequencies being
highly inter-dependent in response to novel stimuli (Haenschel,
Baldeweg, Croft, Whittington, & Gruzelier, 2000). Despite this rich
electrophysiological literature and an emerging picture of the key
molecular and cellular abnormalities in schizophrenia, we are still
faced with the need to link the currently poorly linked pieces of
evidence in order to initiate a systematic investigation of the patho-
physiology of MMN  in schizophrenia.
In light of the correspondence of within-level mechanistic fea-
tures that MMN  generation and schizophrenia have in common,
what recommendations does the literature support in relation to
a strategic or coordinated research approach to linking ﬁndings
across one level to another? First an across-species translational
approach is suggested, especially in relation to phenotype assess-
ment. Ideal measures are ones that can be made in humans,
non-human primates, and rodents. Examples are spatial memory,
task-independent connectivity (e.g., resting-state gamma-band
connectivity analysis; Andreou et al., 2015), and neuronal syn-
chrony (e.g., the auditory steady-state response; Sivarao, 2015)
measures, and of course MMN.  Second, models that link mech-
anisms across at least two levels of description are essential.
Examples of such model building include computational studies
of how synaptic NMDA receptor hypofunction might give rise net-
work level oscillatory deﬁcits indexed in entrainment paradigms
(Kirli et al., 2014) and MMN  (Wacongne, Changeux, & Dehaene,
2012) or experimental studies linking theta oscillatory activity to
somatostatin expressing (Womelsdorf, Valiante, Sahin, Miller, &
Tiesinga, 2014) and multipolar bursting-type (Blatow et al., 2003)
GABAergic interneurons. In relation to recording MMN,  a number
of recommendations have been made (Todd et al., 2013) includ-
ing, (1) use of the random control stimulus sequence to separate
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eviant event at least in clinical studies, (3) use of epidural-placed
lectrodes in rodent studies, and (4) the reporting of standard
nd deviant waveforms separately in addition to difference wave-
orms. Todd et al. (2013) drew attention to the dose-dependency of
MDA receptor antagonist effects and recommended use of a larger
osage range in pharmacologically-induced preclinical models. An
merging theme in the MMN  literature is the value of source-level
odelling of MMN  measures (Fulham et al., 2014; Rissling et al.,
014). The effect of different source modelling methodologies is
llustrated by studies that implicate gamma  band oscillation in the
MN-evoked response (Ballesteros et al., 2013; Nicol et al., 2012)
ersus those that implicate theta band oscillations (Fuentemilla,
arco-Pallares, Munte, & Grau, 2008; Kaser et al., 2013; Ko et al.,
012). Thirdly, there is a need for longitudinal studies of human
evelopment and disease and developmentally and pathophysio-
ogically relevant animal models. The literature draws attention
o the need to investigate a range of animal models that can
ssist in localising the NMDA receptor hypofunction to speciﬁc
ell types and elucidate the temporal order of the glutamater-
ic pathologies observed in postmortem studies of individuals
ith chronic schizophrenia. Validated models are now available to
ssess the NMDA receptor hypofunction across both interneurons
nd pyramidal cells (Featherstone et al., 2015b), in interneurons
nly (Billingslea et al., 2014; Carlen et al., 2012; Korotkova et al.,
010) or in pyramidal cells only (Tatard-Leitman et al., 2015).
Our review also highlights the importance of stage of illness
ffects: in clinical studies, with contrasting results for deviance
ype elicitation of MMN  (Michie et al., 2000); resting state gamma
and connectivity studies (Andreou et al., 2015); source modelling
f MMN  (Fulham et al., 2014); and in pharmacological models of
arly-stage (single dose NMDA receptor antagonist) and late-stage
repeated dose NMDA receptor antagonist) disease (Catts & Catts
010). Importantly, stage-of-illness appears to affect therapeutic
esponse to glutamatergic therapy (Kinon et al., 2015). Our meta-
nalysis revealed a poverty of postmortem studies of the NMDA
eceptor in the auditory cortex in schizophrenia and the need for
ostmortem researchers to broaden their research focus beyond
refrontal and hippocampal regions to include molecular studies of
MDA receptor in the auditory cortex. Research focus may  need to
o beyond the NMDA receptor to include its synaptic and dendritic
artners (e.g., Shelton et al., 2015) as suggested by genetics stud-
es (Fromer et al., 2014; Purcell et al., 2014). We  also highlighted
he limitations of molecular studies in schizophrenia reported to
ate, which have mainly assayed homogenized tissue. There is an
rgent need for ﬁne grained approaches which allow speciﬁcation
f NMDA receptor abnormalities to speciﬁc subunits in speciﬁc
ells, layers and regions at speciﬁc stages of illness. On a more pos-
tive note, our meta-analysis showed for the ﬁrst time the overall
onsistency of the direct postmortem evidence for deﬁcits in NMDA
eceptor expression in schizophrenia, a necessary ﬁrst step in any
ndeavor to link these abnormalities to either MMN  deﬁcits or the
athophysiology of schizophrenia.
In conclusion, while the ﬁeld has begun to identify what may
e consistent molecular changes in NMDA receptor expression in
hronically ill patients with schizophrenia, we still seem a long way
ff from directly linking the observed NMDA receptor hypofunc-
ion in schizophrenia with MMN  changes. Most of the postmortem
tudies on NMDA receptor expression in schizophrenia done to
ate have serious limitations, especially in terms of power, and
esults are understandably inconclusive. But the most striking lim-
tation of the research to date is that few studies have attempted to
ocalize deﬁcits in NMDA receptor expression to either interneu-
ons or pyramidal cells or investigate whether changes occur in
he same people, in the same cell or change according to stage
f illness. While mice with a ∼30% reduction in NR1 expression
cross both interneurons and pyramidal cells show a decreasedology 116 (2016) 57–67
MMN  amplitude (Featherstone et al., 2015b), it remains unknown
whether reduced expression of NMDA receptors in interneurons or
in pyramidal cells on their own is sufﬁcient to elicit reduced MMN
amplitude as seen in individuals with schizophrenia. If so, would
these effects be recapitulated by gene deletion in the auditory cor-
tex alone, or is a cortex-wide expression deﬁcit necessary? What
are the speciﬁc NMDA receptor subunits and downstream signal-
ing processes involved in these effects? The answers to questions
such as these are essential in order to link molecular abnormalities
in schizophrenia to mismatch negativity deﬁcits.
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